US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aardvark Therapeutics

10.36

+0.44004.44%

Post-market: 10.570.2100+2.03%16:56 EST

Volume:206.93K

Turnover:2.13M

Market Cap:224.78M

PE:-15.99

High:10.94

Open:9.97

Low:9.92

Close:9.92

52wk High:19.58

52wk Low:4.88

Shares:21.70M

Float Shares:5.89M

Volume Ratio:1.98

T/O Rate:3.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6480

EPS(LYR):-0.7400

ROE:-33.09%

ROA:-21.76%

PB:1.64

PE(LYR):-14.00

Loading ...

Overview Company News Filings

Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics

U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair

Aardvark Therapeutics Initiated at Buy by Stifel

Aardvark Therapeutics Inc : Stifel Initiates Coverage With Buy Rating: Target Price $24

THOMSON REUTERS

Stifel Initiates Aardvark Therapeutics at Buy With $24 Price Target

MT Newswires Live

Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment

Aardvark Therapeutics Inc. to Present at Stifel 2025 Virtual Cardiometabolic Forum

Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Aardvark Therapeutics CEO Makes Bold Stock Purchase

CFO Makes Bold Move with Major Stock Purchase in Aardvark Therapeutics!

LB Pharmaceuticals raises $285 million in US IPO

CFO Nelson Sun Reports Acquisition of Common Shares in Aardvark Therapeutics Inc

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Is Maintained at Buy by B of A Securities

Aardvark Therapeutics Inc. to Present at Cantor Fitzgerald Global Healthcare Conference 2025 in New York

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

LIVE MARKETS-Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says

RBC Capital Adjusts Price Target on Aardvark Therapeutics to $19 From $20, Maintains Outperform Rating

MT Newswires Live

Aardvark Therapeutics Q2 Loss Narrows

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AARD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":10.36,"timestamp":1763413200000,"preClose":9.92,"halted":0,"volume":206931,"hourTrading":{"tag":"盘后","latestPrice":10.57,"preClose":10.36,"latestTime":"16:56 EST","volume":818,"amount":8607.989051999999,"timestamp":1763416612097},"delay":0,"floatShares":5888000,"shares":21696893,"eps":-0.648,"marketStatus":"Post-Mkt","change":0.44,"latestTime":"11-17 17:44:27 EST","open":9.97,"high":10.94,"low":9.92,"amount":2134350.068748,"amplitude":0.102823,"askPrice":11.5,"askSize":650,"bidPrice":9.33,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.648,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763427600000},"marketStatusCode":4,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":9.92,"postHourTrading":{"tag":"盘后","latestPrice":10.57,"preClose":10.36,"latestTime":"16:56 EST","volume":818,"amount":8607.989051999999,"timestamp":1763416612097},"volumeRatio":1.975479},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-21.76%","roe":"-33.09%","lyrEps":-0.74,"volumeRatio":1.975479,"shares":21696893,"dividePrice":0,"high":10.94,"amplitude":0.102823,"preClose":9.92,"low":9.92,"week52Low":4.88,"pbRate":"1.64","week52High":19.58,"institutionHeld":0,"latestPrice":10.36,"committee":-0.733333,"eps":-0.648,"divideRate":0,"volume":206931,"delay":0,"ttmEps":-0.648,"open":9.97,"prevYearClose":16,"prevWeekClose":9.92,"prevMonthClose":10.69,"prevQuarterClose":13.29,"fiveDayClose":10.44,"twentyDayClose":12.28,"sixtyDayClose":9.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2025-11-14","current":-15.910494,"percent":0.819149,"low":-51.17654,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"high":-4.61321,"avg":-12.415283,"sd":9.740001,"marketCap":236457733},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733}],"updateTime":1763411658908},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2572582604","title":"Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2572582604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572582604?lang=en_us&edition=fundamental","pubTime":"2025-10-01 16:55","pubTimestamp":1759308941,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has received a new Buy rating, initiated by JonesTrading analyst, Catherine Novack. Catherine Novack’s rating is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-positioning-drive-buy-rating-for-aardvark-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-positioning-drive-buy-rating-for-aardvark-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2572442589","title":"U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair","url":"https://stock-news.laohu8.com/highlight/detail?id=2572442589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572442589?lang=en_us&edition=fundamental","pubTime":"2025-10-01 15:33","pubTimestamp":1759304007,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair Oct 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carvana","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nL5N3VI0DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFH","AXSM","HHH","AJG","MMC","DEI","ADSK","NAVI","FIS","TOST","BILL","LW","CHYM","WU","EEFT","ZETA","LIF","CPAY","SLM","OMC","BLDR","POOL","IPG","CVNA","BSX","BRO","AXP","AARD","JKHY","MTSI","MQ","PDM","MRCY","ALLY","UPWK","FOUR","MRVL","PTGX","ARCB","LU2238339852.HKD","BWIN","ZYME","SMTC","PAYX","HROW","SYF"],"gpt_icon":1},{"id":"2571337072","title":"Aardvark Therapeutics Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2571337072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571337072?lang=en_us&edition=fundamental","pubTime":"2025-09-29 22:59","pubTimestamp":1759157940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 10:59 ET (14:59 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4127","AARD"],"gpt_icon":0},{"id":"2571387970","title":"Aardvark Therapeutics Inc : Stifel Initiates Coverage With Buy Rating: Target Price $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387970?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:15","pubTimestamp":1759144533,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG03A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2571938796","title":"Stifel Initiates Aardvark Therapeutics at Buy With $24 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2571938796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571938796?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:14","pubTimestamp":1759144461,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has an average rating of buy and mean price target of $31.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD","SF"],"gpt_icon":0},{"id":"2571388768","title":"Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2571388768","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571388768?lang=en_us&edition=fundamental","pubTime":"2025-09-29 16:35","pubTimestamp":1759134958,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has received a new Buy rating, initiated by Stifel Nicolaus analyst, James Condulis. James Condulis has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-aardvark-therapeutics-ard-101s-potential-in-prader-willi-syndrome-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-aardvark-therapeutics-ard-101s-potential-in-prader-willi-syndrome-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARD","AARD"],"gpt_icon":0},{"id":"2569745975","title":"Aardvark Therapeutics Inc. to Present at Stifel 2025 Virtual Cardiometabolic Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2569745975","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569745975?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:05","pubTimestamp":1758657910,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:00 a.m. Eastern time. The company focuses on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. A live webcast presentation will be accessible on Aardvark's website, with an archived recording available for approximately one month following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 23, 2025, and is solely responsible for the information contained therein","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL6rMvpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","AARD","NDAQ","LU2210150020.SGD"],"gpt_icon":0},{"id":"2569792679","title":"Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2569792679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569792679?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:26","pubTimestamp":1758626760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 23, 2025 07:26 ET (11:26 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2568455564","title":"Aardvark Therapeutics CEO Makes Bold Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2568455564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568455564?lang=en_us&edition=fundamental","pubTime":"2025-09-17 10:07","pubTimestamp":1758074872,"startTime":"0","endTime":"0","summary":"New insider activity at Aardvark Therapeutics, Inc. ( ($AARD) ) has taken place on September 16, 2025. CEO Lee Tien-Li has made a significant inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/aardvark-therapeutics-ceo-makes-bold-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/aardvark-therapeutics-ceo-makes-bold-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2566693214","title":"CFO Makes Bold Move with Major Stock Purchase in Aardvark Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2566693214","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566693214?lang=en_us&edition=fundamental","pubTime":"2025-09-11 10:10","pubTimestamp":1757556607,"startTime":"0","endTime":"0","summary":"New insider activity at Aardvark Therapeutics, Inc. ( ($AARD) ) has taken place on September 10, 2025. CFO Nelson Sun has made a significant invest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cfo-makes-bold-move-with-major-stock-purchase-in-aardvark-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cfo-makes-bold-move-with-major-stock-purchase-in-aardvark-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2566316759","title":"LB Pharmaceuticals raises $285 million in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2566316759","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566316759?lang=en_us&edition=fundamental","pubTime":"2025-09-11 09:18","pubTimestamp":1757553524,"startTime":"0","endTime":"0","summary":"UPDATE 1-LB Pharmaceuticals raises $285 million in US IPOAdds details from paragraph 2 onwardsSept 10 (Reuters) - LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3N3UY02N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","MNSH","SF","BK4127","PIPR","AARD"],"gpt_icon":0},{"id":"2566980616","title":"CFO Nelson Sun Reports Acquisition of Common Shares in Aardvark Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2566980616","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566980616?lang=en_us&edition=fundamental","pubTime":"2025-09-11 05:36","pubTimestamp":1757540203,"startTime":"0","endTime":"0","summary":"Nelson Sun, Chief Financial Officer of Aardvark Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL5llZ3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2565680305","title":"LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought","url":"https://stock-news.laohu8.com/highlight/detail?id=2565680305","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565680305?lang=en_us&edition=fundamental","pubTime":"2025-09-08 22:37","pubTimestamp":1757342232,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector droughtSept 8 (Reuters) - Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL6N3UT02O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4207","SF","BK4127","MNSH","AARD"],"gpt_icon":0},{"id":"2564371766","title":"Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564371766","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564371766?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:00","pubTimestamp":1756987200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  04, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/04/3144439/0/en/Aardvark-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-C-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0980610538.SGD","NDAQ","PSQ","LU2360032135.SGD","LU0648001328.SGD","TSYW.SI","AARD","QID","LU0128525689.USD","BK4504","QLD","LU1244550577.SGD","IE00BSNM7G36.USD","LU0106831901.USD","MNQmain","LU1366192091.USD","LU2125154935.USD","NVIW.SI","BK4566","NQmain","LU1668664300.SGD","SQQQ","BK4559","TQQQ",".IXIC","LU0052756011.USD","LU1162221912.USD","LU0130102774.USD","USAW.SI","LU0162691827.USD","LU0170899867.USD","LU2125154778.USD","LU2462157665.USD","IE00B64PRP62.GBP","BK4585","LU0130517989.USD","BK4112","BK4534","LU0098860793.USD","LU1244550494.USD","LU2210150020.SGD","LU0477156953.USD","LU2417539215.USD","LU2236285917.USD","USJW.SI","LU0314104364.USD","IE00B3QW5Z07.USD","LU1244550221.USD","LU0072461881.USD"],"gpt_icon":1},{"id":"2563054170","title":"Aardvark Therapeutics Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2563054170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563054170?lang=en_us&edition=fundamental","pubTime":"2025-08-29 00:01","pubTimestamp":1756396860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 28, 2025 12:01 ET (16:01 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2562672797","title":"Aardvark Therapeutics Inc. to Present at Cantor Fitzgerald Global Healthcare Conference 2025 in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2562672797","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562672797?lang=en_us&edition=fundamental","pubTime":"2025-08-28 04:10","pubTimestamp":1756325409,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, will present at the Cantor Fitzgerald Global Healthcare Conference 2025 in New York. The presentation is scheduled for Wednesday, September 3 at 11:30 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL2ZD1yp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","AARD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2559963268","title":"Aardvark Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2559963268","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559963268?lang=en_us&edition=fundamental","pubTime":"2025-08-14 23:28","pubTimestamp":1755185280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 11:28 ET (15:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2559639709","title":"LIVE MARKETS-Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says","url":"https://stock-news.laohu8.com/highlight/detail?id=2559639709","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559639709?lang=en_us&edition=fundamental","pubTime":"2025-08-14 23:20","pubTimestamp":1755184836,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink saysS&P 500, Nasdaq edge red; Dow modestly lowerMaterials weakest S&P sector; Comm Svcs leads gainersEuro STOXX 600 index up ~0.5%Dollar rallies; crude up >1%; gold dips; bitcoin slides >3%US 10-Year Treasury yield rises to ~4.28%Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL4N3U6140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AARD","BK4585","BK4139","LU2065170008.USD","LU2065171311.SGD","RYTM","LU2065171402.SGD","ACAD","SLNO","LU2065169927.USD"],"gpt_icon":0},{"id":"2559951842","title":"RBC Capital Adjusts Price Target on Aardvark Therapeutics to $19 From $20, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2559951842","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559951842?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:10","pubTimestamp":1755169809,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD-US) has an average rating of buy and mean price target of $32.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2559812429","title":"Aardvark Therapeutics Q2 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2559812429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559812429?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:48","pubTimestamp":1755118091,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  reported a Q2 loss Wednesday of $0.66 per diluted share, narrowing from $1.37 a year earlier.Analysts surveyed by FactSet expected a loss of $0.60.The company did not report any revenue for the quarter ended June 30.As of June 30, the company said it had $141.8 million in cash, cash equivalents, and short-term investments, expected to fund operations into 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":55,"code":"91000000","status":"200"}]}}